Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.

Delaying noncardiac surgeries for three to six months following a heart attack appears safer for those who undergo r ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

The study highlights BMI's role in mediating genetic risk for diseases, suggesting a complex relationship with conditions ...

In MI patients with preserved heart function, beta-blockers are linked to higher depressive symptoms, indicating a need for ...

WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

A history of HDP is linked to increased risks of myocardial infarction, whether that’s with obstructive coronary arteries or ...

In the ABYSS trial, researchers found that interrupting a beta-blocker in patients after a myocardial infarction resulted in ...

Women aged less than 50 years hospitalized with MI have gender-specific cardiovascular risk factors and experience typical chest pain.

New research has shown that acute anaemia is associated with a 25% higher risk of a composite outcome of 30-day death or ...